Irrespective of its benefit, the US drug advisers were of the view that Johnson and Johnson's Ortho Evra birth control patch should clearly indicate about risks it possess for women, like the potential danger of blood clots.

Some of the experts have even recommended that it should be banned in the US market. Being a sole birth patch product in the US market and seeing its potential benefits, the FDA advisory panel has said that it should not get banned.

Its benefits are more than its risks and this factor should be considered before the FDA takes any decision on this topic. The debate started at the time when the FDA presented its report in October that this patch contains drospirenone which is associated with risk of venous thromboembolism (VTE).

VTE risk is quite less in hormonal contraceptives and level of estrogen is also less in them in comparison to the Ortho Evra patch. Increasingly women are opting for the patch and it is said that 55% of women who use it are at an increased risk of getting contracted with VTE, said Stephen Sidney who is lead author on the FDA report.

There are other factors also for increased risk of blood clots in the women, said MD of the FDA's Division of Reproductive and Urologic Products, Lisa Soule. She further affirmed that age, health and medical conditions are among the prime factors of witnessing blood clots.

Every birth control bring brings risk of blood clots, but matter is that the patch is said to be having higher risk of getting blood clots. For which one of the panel members affirmed, "I'm satisfied generally with what the content is for this label, it's the understandability and presentation that needs some work".

It is expected that the FDA would go with its advisory panel, as always.